学术会议:紧随研究趋势 洞察学术热点 进入>
产业会议:新技术,新领域,深入产业环节 进入>
举办会议及论坛超过百场 邀请海内外院士超过50名 教授PI专家授课超过1000名 总参会人数超过10万人
2019-05-17至2019-05-18 上海
导航

已确认嘉宾Confirmed Guests

Li Zhou VP of Cell Therapy and Antibody research

Luye Boston R&D

Li Zhou VP of Cell Therapy and Antibody research

Luye Boston R&D

Li Zhou, PhD, VP of Cell Therapy and Antibody research at Luye Boston R&D. He was previously VP of CAR-T Cell Therapy at Livzon Mabpharm in Zhuhai Guangdong. His team established the lentivector and CAR-T GMP manufacturing platforms and advanced the first internal CAR-T program into the IND enabling clinical study.  As VP of Cell Engineering at TxCell (now is Sangamo therapeutics) in France, he led the team quickly built a diverse CAR-Treg product pipeline for treating autoimmune disease and organ transplant rejection. His team helped advancing the first-ever CAR-Treg clinical trial for prevention of organ transplant rejection. As CSO and Director of Research at ZMKS international Cancer Therapy Biotechnologies Co., he pioneered the effort in engineering the armed CAR-T cells that can secrete bispecific checkpoint inhibitor antibodies. Prior to this, he was investigator III/lab head in Novartis Biologics Center in Cambridge working on developing bispecific antibody therapeutics, and  CAR-T therapies. He led a number of CAR-T programs including CD22 CAR-T, bispecific CD19/CD22 CAR-T to treat antigen negative relapse in blood cancers, Mesothelin CAR-T against solid tumors, as well as on-switch regulatable CAR-T program. Dr Zhou received his BS and MS from Nankai University and PhD from Beijing University.

 


邀请函

下载邀请函
×
留下姓名电话和邮箱,邀请函直接发送到邮箱
*姓名:
* 电话:
* Email: